RESUMO
Objectives: Compare outcomes with methotrexate (MTX) or etanercept (ETN) monotherapy in Japanese patients with active rheumatoid arthritis (RA) who were MTX-naïve or with intolerance or inadequate response to prior MTX (MTX-IR).Methods: Post hoc analysis of a phase 3 study comparing MTX, ETN 10 mg twice weekly, and ETN 25 mg twice weekly in Japanese patients with RA. Disease activity was evaluated using American College of Rheumatology (ACR) scores and 28-joint Disease Activity Score (DAS28), radiographic progression evaluated using van der Heijde's modified Total Sharp Score (mTSS), and functional status evaluated using Health Assessment Questionnaire Disability Index (HAQ-DI).Results: Among MTX-naïve and MTX-IR patients, greater proportions of those randomized to either ETN group achieved ACR20, ACR50, ACR70, DAS28 ≤3.2 or <2.6, clinically relevant inhibition of mTSS changes, and reductions in HAQ-DI compared with MTX at the majority of time points. There were very few clinically meaningful differences between ETN groups for any of the variables evaluated.Conclusion: ETN monotherapy was more effective than MTX in both MTX-naïve and MTX-IR patients, with very few clinically meaningful differences between ETN 10 mg and ETN 25 mg when given twice weekly. The relative benefits of ETN were greater in MTX-naïve patients than MTX-IR patients.ClinicalTrials.gov identifierNCT00445770.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Etanercepte/uso terapêutico , Adulto , Antirreumáticos/administração & dosagem , Antirreumáticos/efeitos adversos , Artrite Reumatoide/diagnóstico por imagem , Artrite Reumatoide/patologia , Etanercepte/administração & dosagem , Etanercepte/efeitos adversos , Feminino , Humanos , Japão , Masculino , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
OBJECTIVES: The objective of this study is to clarify the surgical indication for rheumatoid forefoot deformity according to background characteristics and plantar pressure. METHODS: Patients with rheumatoid arthritis were divided into a non-surgical group (group N) and a surgical group (group S). The former consisted of 225 ft, and the latter consisted of 88 ft. DAS28, Japanese Society for Surgery of the Foot rheumatoid arthritis foot and ankle scale (JSSF scale) and hallux valgus angle (HVA) were evaluated as background characteristics. Distribution of peak pressure as plantar pressure was measured in nine sections. RESULTS: In groups N and S, the mean DAS28 was 3.6 and 3.0, the mean JSSF scale was 81.1 and 63.0, and the mean HVA was 19.9° and 35.3°, respectively. The mean peak pressure of group S at the first and third metatarsophalangeal joints was significantly higher compared with group N. Significant differences between the two groups were also seen in Δ pressure (the difference between the maximum and minimum peak pressure values). The cut-off values were 75.0 for JSSF scale, 24.9° for HVA and 3.94 kg/cm2 for Δ pressure. CONCLUSIONS: The combined assessment of HVA and Δ pressure was found to be useful as an indication for surgical treatment of the forefoot.
Assuntos
Artrite Reumatoide/cirurgia , Artroplastia/efeitos adversos , Deformidades Adquiridas do Pé/cirurgia , Hallux Valgus/cirurgia , Adulto , Artrite Reumatoide/complicações , Artrite Reumatoide/patologia , Artroplastia/métodos , Feminino , Deformidades Adquiridas do Pé/etiologia , Deformidades Adquiridas do Pé/patologia , Humanos , Masculino , Articulação Metatarsofalângica/cirurgia , Pessoa de Meia-Idade , Complicações Pós-Operatórias/prevenção & controle , PressãoRESUMO
OBJECTIVES: To compare MRI findings in rheumatoid arthritis (RA) patients treated with biologic disease-modifying anti-rheumatic drugs (DMARDs). METHODS: The study subjects were 43 RA patients treated with biologic DMARDs (13 with infliximab, 15 with tocilizumab, and 15 with abatacept). They were evaluated using Simplified Disease Activity Index (SDAI) and low-field extremity MRI at baseline, and at 24 weeks and 52 weeks of treatment. RESULTS: Synovitis scores were significantly lower by 24 weeks in all groups, compared with baseline (P < 0.05). Significant improvement in bone marrow edema (BME) scores were noted from baseline to 24 weeks in infliximab and abatacept groups (P < 0.05), but from 24 weeks to 52 weeks in tocilizumab group (P < 0.01). No significant change was found in erosion score. The synovitis score at baseline correlated significantly with SDAI at 24 weeks (P < 0.05), and the score at 24 weeks correlated significantly with SDAI at 52 weeks (P < 0.05). CONCLUSIONS: The results suggest that the inflammatory improvement by infliximab and abatacept may express earlier than those by tocilizumab, despite similar improvement in SDAI. MRI-detected synovitis could be a useful predictor of SDAI at 24 weeks of treatment. The MRI remains the best tool to detect and assess the effects of biologic DMARDs in RA.
Assuntos
Abatacepte/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Medula Óssea/patologia , Infliximab/uso terapêutico , Adulto , Idoso , Artrite Reumatoide/patologia , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
OBJECTIVE: To examine the role of vascular endothelial growth factor (VEGF) and angiopoietin signaling in the diagnosis and disease outcome of patients with early arthritis. METHODS: Fifty patients with early arthritis (disease duration <1 year) who had not been treated with disease-modifying antirheumatic drugs (DMARDs) were monitored prospectively and were classified at baseline and after 2 years as having undifferentiated arthritis (UA), rheumatoid arthritis (RA), or spondyloarthritis (SpA). All patients underwent arthroscopic synovial biopsy at baseline. Synovial expression of VEGF, VEGF receptor, angiopoietin 1 (Ang-1), Ang-2, TIE-2, and activated p-TIE-2 was evaluated by immunohistochemistry. Serum levels of VEGF, Ang-1, and Ang-2 were measured by enzyme-linked immunosorbent assay. Secreted products of macrophages stimulated with Ang-1 and Ang-2 were measured using a multiplex system. RESULTS: Expression of Ang-1 was comparable between the patients with RA at baseline and patients with UA who fulfilled the criteria for RA over time (UA/RA), and it was significantly higher in patients with RA (P < 0.05) or UA/RA (P < 0.005) than in patients with SpA. TIE-2 and p-TIE-2 were more highly expressed in patients with RA (P < 0.005) or UA/RA (P < 0.05) than in patients with SpA. Ang-1 significantly enhanced the tumor necrosis factor-dependent macrophage production of cytokines and chemokines that are known to be elevated in the synovial fluid of patients with early RA. In RA, relative TIE-2 activation predicted the development of erosive disease (R(2) = 0.35, P < 0.05). CONCLUSION: Local engagement of synovial TIE-2 is observed during the earliest phases of RA, suggesting that TIE-2 signaling may contribute to disease development and progression or may indicate an attempt to protect against these processes. Early therapeutic targeting of TIE-2 signaling may be useful in improving outcome in arthritis.
Assuntos
Artrite Reumatoide/metabolismo , Receptor TIE-2/metabolismo , Membrana Sinovial/metabolismo , Adulto , Angiopoietina-1/metabolismo , Angiopoietina-2/metabolismo , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/patologia , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Receptores de Fatores de Crescimento do Endotélio Vascular/metabolismo , Espondilartrite/tratamento farmacológico , Espondilartrite/metabolismo , Espondilartrite/patologia , Membrana Sinovial/patologia , Resultado do TratamentoRESUMO
Affection of radio-carpal joint is most frequently revealed in patients, suffering rheumatoid arthritis. While the disease progressing in almost 75% of patients the inflammatory changes in radio-carpal joint occur. An acute and chronic synovitis, damage of a cartilage constitute a cause of a typical erosion of bones inside a joint, weakening of a tendo-ligamentous apparatus and its further deformity. Operative treatment was aimed for the inflammatory focus elimination, reduction of the pain syndrome severity, the function loss, and the joint deformity correction. The mostly used operative interventions are tenoectomy, synovectomy, arthrodesis, total endoprosthesis.
Assuntos
Artrite Reumatoide/cirurgia , Articulações do Carpo/cirurgia , Deformidades Articulares Adquiridas/cirurgia , Rádio (Anatomia)/cirurgia , Adulto , Artrite Reumatoide/patologia , Artrodese , Artroplastia , Artroplastia de Substituição , Articulações do Carpo/patologia , Feminino , Humanos , Deformidades Articulares Adquiridas/patologia , Prótese Articular , Masculino , Pessoa de Meia-Idade , Rádio (Anatomia)/patologia , Amplitude de Movimento Articular/fisiologia , Resultado do Tratamento , Adulto JovemRESUMO
Type III collagen gene expression is upregulated in the synovium of patients with rheumatoid arthritis (RA) presenting the fibroid phenotype. The soluble type III collagen formation biomarker, PRO-C3, is known to measure fibrogenesis in fibrotic diseases. In this exploratory study, we aimed to investigate the association between fibrogenesis (PRO-C3) and the disease- and treatment response in patients with RA. We measured PRO-C3 in subsets of two clinical trials assessing the effect of the anti-interleukin-6 (IL-6) receptor treatment tocilizumab (TCZ) as monotherapy or polytherapy with methotrexate. PRO-C3 levels had weak or very weak correlations with the clinical parameters (Spearman's). However, when the patients were divided into Disease Activity Score-28 groups characterized by the erythrocyte sedimentation rate (DAS28-ESR), there was a statistical difference between the PRO-C3 levels of the different groups (p < 0.05). To determine the response in relation to PRO-C3, a cut-off based on PRO-C3 levels and patients in remission (DAS28-ESR ≤ 2.6) was identified. This showed that a reduction in PRO-C3 after treatment initiation was associated with decreased DAS28-ESR and a higher response rate in patients with low PRO-C3 levels than in those with high PRO-C3 levels. This indicates that a fibrotic component affects the responsiveness of patients.
Assuntos
Anticorpos Monoclonais Humanizados , Antirreumáticos , Artrite Reumatoide , Receptores de Interleucina-6 , Humanos , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/metabolismo , Artrite Reumatoide/patologia , Feminino , Receptores de Interleucina-6/metabolismo , Receptores de Interleucina-6/antagonistas & inibidores , Masculino , Pessoa de Meia-Idade , Anticorpos Monoclonais Humanizados/uso terapêutico , Antirreumáticos/uso terapêutico , Metotrexato/uso terapêutico , Fenótipo , Biomarcadores , Adulto , Idoso , Resultado do TratamentoRESUMO
A 67-year-old woman with rheumatoid arthritis (RA; Steinblocker stage IV, class 4) who had RA onset at 34 years of age had anterior thigh pain, femoral neuropathy and lower abdominal pain. Physical examination showed multidirectional limit of motion, and radiographic examination showed destruction of the hip joint. MRI and arthrography indicated a cystic lesion that communicated with the hip joint. The rheumatoid synovial cyst was removed during total hip arthroplasty. The symptoms were relieved, and the mass was reduced in size.
Assuntos
Artrite Reumatoide/complicações , Articulação do Quadril/patologia , Cisto Sinovial/complicações , Idoso , Artrite Reumatoide/patologia , Artroplastia de Quadril , Feminino , Articulação do Quadril/cirurgia , Humanos , Imageamento por Ressonância Magnética , Cisto Sinovial/patologia , Cisto Sinovial/cirurgia , Resultado do TratamentoRESUMO
OBJECTIVE: To identify the value of magnetic resonance imaging (MRI)-proven bone edema in patients with very early rheumatoid arthritis (RA). METHODS: All of the 13 patients included in the study were positive at entry for MRI-proven bone edema of the wrist and finger joints and anti-cyclic citrullinated peptide antibodies or IgM-rheumatoid factor. A tight control approach was applied for 12 months. Plain MRI and radiographs of both wrist and finger joints were examined every 6 months. MRI was scored by the RA MRI scoring (RAMRIS) technique and plain radiographs were scored using the Genant-modified Sharp score. Variables that were correlated with plain radiographic changes at 12 months were examined. RESULTS: Simplified disease activity index (SDAI) remission was achieved in 7 patients, and a significant reduction in the RAMRIS bone edema score, which declined to <33 % as compared with the baseline, was achieved in 8 out of 13 patients. Four patients showed plain radiographic progression while 9 patients did not. Significant reductions in the RAMRIS bone edema score (p = 0.007) and the time-integrated SDAI (p = 0.031) were the variables involved in plain radiographic progression. CONCLUSIONS: Improvement in bone edema may be associated with protection against structural damage in very early RA patients managed using the tight control approach.
Assuntos
Artrite Reumatoide/patologia , Doenças Ósseas/patologia , Edema/patologia , Articulações dos Dedos/patologia , Articulação do Punho/patologia , Adulto , Idoso , Antirreumáticos/uso terapêutico , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Doenças Ósseas/diagnóstico por imagem , Doenças Ósseas/etiologia , Progressão da Doença , Edema/diagnóstico por imagem , Edema/etiologia , Feminino , Articulações dos Dedos/diagnóstico por imagem , Humanos , Imageamento por Ressonância Magnética , Masculino , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Radiografia , Sulfassalazina/uso terapêutico , Tacrolimo/uso terapêutico , Resultado do Tratamento , Articulação do Punho/diagnóstico por imagemRESUMO
Arthroscopy is a technique that can be used in rheumatoid arthritis, regarding for indications with diagnostic purposes--synovial membrane macroscore and biopsy with following histological examination. Changes in the synovium in rheumatoid arthritis are localized in the lateral and anterior parts of the knee, where hyperemia, rheumatoid pannus growth, hypertrophic clavate villus are often seen. It also can be used for therapeutic purposes--synovectomy in combination with flushing of the knee. After the arthroscopy with debridment in patients with rheumatoid arthritis, pain syndrome, swelling and the amount of effusion in the joint is significantly reduced or eliminated, amplitude of movements increases, functional activity of the limbs restores.
Assuntos
Artrite Reumatoide , Artroscopia/métodos , Artrite Reumatoide/patologia , Artrite Reumatoide/cirurgia , Humanos , Articulação do Joelho/patologia , Articulação do Joelho/cirurgia , Amplitude de Movimento Articular/fisiologia , Sinovectomia , Resultado do TratamentoRESUMO
OBJECTIVE: To evaluate the effects of golimumab on inflammation/structural damage detected by magnetic resonance imaging (MRI) in patients with rheumatoid arthritis (RA). METHODS: Methotrexate (MTX)-naive RA patients (n = 637) were randomized to placebo plus MTX, golimumab 100 mg plus placebo, golimumab 50 mg plus MTX, or golimumab 100 mg plus MTX (subcutaneous golimumab every 4 weeks). Of these, 318 patients participated in an MRI substudy. MRIs (contrast-enhanced; 1.5T) of the wrist and second through fifth metacarpophalangeal joints of the dominant hand were obtained at baseline and weeks 12 and 24. MRIs were scored by 2 independent readers (blinded to image sequence/chronology, patient identity, and treatment group) for synovitis, bone edema/osteitis, and bone erosions using the Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) system. Radiographs (hands, wrists, forefeet at baseline and week 28) were scored by 2 other readers (blinded as above) using the modified Sharp/van der Heijde (SvdH) scoring system. Changes from baseline were compared between treatment groups (two-sided analysis of variance on van der Waerden normal scores). RESULTS: At weeks 12 and 24, combined therapy with golimumab plus MTX versus placebo plus MTX significantly improved RAMRIS scores for synovitis (mean -1.92 versus 0.14 [P < 0.001] at week 12; -2.45 versus -1.04 [P < 0.001] at week 24), osteitis (mean -1.82 versus 0.56 [P < 0.001] at week 12; -2.27 versus -0.32 [P < 0.001] at week 24), and bone erosion (mean -0.40 versus 0.24 [P = 0.016] at week 12; -0.40 versus -0.24 [P = 0.010] at week 24). Results of sensitivity analyses (no missing doses/data and using linear extrapolation) were generally consistent with results of the primary analyses. Changes in SvdH scores among the MRI substudy patients at week 28 showed no significant difference between golimumab plus MTX therapy and placebo plus MTX (mean 0.49 versus 0.92; P = 0.19). Radiographic SvdH scores demonstrated inhibition of structural damage progression by treatment with golimumab plus MTX as compared with placebo plus MTX in the overall study population but required double the number of patients (637 versus 318) and double the length of followup (28 versus 12 weeks) as needed for MRI to demonstrate this. CONCLUSION: Improvements in inflammation (synovitis and osteitis) and erosions with golimumab plus MTX therapy exceeded those with placebo plus MTX therapy from week 12 onward, confirming the overall clinical/radiologic findings. MRI was more sensitive than conventional radiography in detecting the progression of erosions.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/patologia , Reabsorção Óssea/tratamento farmacológico , Metotrexato/uso terapêutico , Osteíte/tratamento farmacológico , Sinovite/tratamento farmacológico , Adulto , Antirreumáticos/uso terapêutico , Artrite Reumatoide/complicações , Reabsorção Óssea/etiologia , Reabsorção Óssea/patologia , Progressão da Doença , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Articulação Metacarpofalângica/patologia , Pessoa de Meia-Idade , Osteíte/etiologia , Osteíte/patologia , Sinovite/etiologia , Sinovite/patologia , Resultado do Tratamento , Articulação do Punho/patologiaRESUMO
Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of anakinra is to competitively inhibit the local inflammatory effects of IL-1. Kineret is generally safe and well tolerated and the only major treatment-related side effects that appear are skin reactions at the injection site. Due to the relatively short half-life of anakinra, daily injection of the drug is required. This, in combination with the comparably high rates of injection-site reactions (ISRs) associated with the drug, can become a problem for the patient. The present review summarises published data concerning ISRs associated with Kineret and provides some explanations as to their cause. The objective is also to present some clinical experiences of how the ISRs can be managed.
Assuntos
Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Toxidermias/etiologia , Proteína Antagonista do Receptor de Interleucina 1/administração & dosagem , Proteína Antagonista do Receptor de Interleucina 1/efeitos adversos , Artrite Reumatoide/patologia , Relação Dose-Resposta a Droga , Toxidermias/tratamento farmacológico , Toxidermias/prevenção & controle , Humanos , Injeções Subcutâneas/efeitos adversos , Injeções Subcutâneas/métodos , Injeções Subcutâneas/normasRESUMO
Rice body formation is a nonspecific response to chronic synovial inflammation associated with tuberculous arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, seronegative inflammatory arthritis, and even osteoarthritis. Such bodies were termed rice bodies because of their close resemblance to grains of polished white rice. We present a case report of a middle-aged woman with right shoulder subacromial/subdeltoid bursitis with giant rice body formation as her initial presentation of rheumatoid arthritis. Her right shoulder symptoms resolved after subacromial and subdeltoid bursectomy and removal of the rice bodies. She subsequently developed inflammatory arthritis of other joints, met the criteria for rheumatoid arthritis, and has been treated medically.
Assuntos
Articulação Acromioclavicular/patologia , Artrite Reumatoide/diagnóstico por imagem , Artrite Reumatoide/patologia , Bursite/patologia , Articulação Acromioclavicular/diagnóstico por imagem , Articulação Acromioclavicular/cirurgia , Bolsa Sinovial/patologia , Bolsa Sinovial/cirurgia , Bursite/diagnóstico por imagem , Bursite/cirurgia , Feminino , Humanos , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Radiografia , Resultado do TratamentoRESUMO
We present the case of a 56-year-old woman with a one-month history of recurrent, migratory oligoarthritis. Laboratory tests were normal except for positive antinuclear antibody (ANA) titers. Imaging studies were normal. Palindromic rheumatism (PR) was considered as a diagnosis. In this brief report, we discuss the etiopathogenesis, clinical presentation, prognosis and treatment of this entity. We also elaborate on the factors associated with progression to chronic joint disease. It is important for the primary care physician to be aware of this relatively uncommon diagnosis in patients presenting with joint pains and to distinguish it from other causes of recurrent arthritis, especially rheumatoid arthritis (RA).
Assuntos
Artrite Reumatoide , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/patologia , Diagnóstico Diferencial , Feminino , Humanos , Pessoa de Meia-Idade , RecidivaRESUMO
Biologics have proven to be an effective treatment option for adults with rheumatoid arthritis but their use in clinical practice may be limited by concerns over severe side effects and cost. Pharmacology and development of biomarkers could help to optimize the use of biologics in clinical practice. Biomarkers are surrogate markers and include all diagnostic tests, imaging and technologies and any other objective measure of a person's health status and all pharmacodiagnostic tests. Several studies evaluated interest of biomarkers in RA patients treated with biologics: 1- to optimize doses and frequency of drug administration; 2- to predict response to treatment; 3- to predict tolerance of biologics; 4- to monitor patient who stopped treatment and are in remission, and predict new RA flare.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/imunologia , Produtos Biológicos/uso terapêutico , Anticorpos/análise , Anticorpos Monoclonais Murinos/uso terapêutico , Antirreumáticos/efeitos adversos , Antirreumáticos/farmacocinética , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/patologia , Produtos Biológicos/efeitos adversos , Produtos Biológicos/farmacocinética , Biomarcadores , Análise Custo-Benefício , Previsões , Humanos , Rituximab , Resultado do TratamentoRESUMO
The Sauvé-Kapandji (S-K) procedure is a common treatment for rheumatoid wrists, but in some cases severe bone destruction makes this operative modality difficult to perform, while also resulting in a poor outcome. A modified S-K procedure for these wrists has been reported, but the clinical outcomes of the modified procedure are unclear. This study evaluated 24 wrists in 20 patients who underwent the modified S-K procedure. The mean follow-up period was 34.5 months. The clinical assessments were range of motion, carpal bone translation and bony shelf size. The range of motion and carpal bone translation were similar to those produced by the S-K procedure. In regard to bony shelf size, wrists with an excessively large bony shelf tended to have a progression of carpal bone translation toward the palmar direction due to the residual malposition of the ECU tendon. The modified S-K procedure appears to be a safe and effective surgical alternative for the treatment of severely destroyed rheumatoid wrists. Although the modified procedure allows for the adjustment of the bony shelf size, it should not be used with wrists that have an excessively large bony shelf.
Assuntos
Artrite Reumatoide/cirurgia , Ossos do Carpo/cirurgia , Osteotomia , Articulação do Punho/cirurgia , Adulto , Idoso , Artrite Reumatoide/patologia , Parafusos Ósseos , Transplante Ósseo , Ossos do Carpo/diagnóstico por imagem , Ossos do Carpo/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Radiografia , Amplitude de Movimento Articular , Resultado do Tratamento , Articulação do Punho/diagnóstico por imagem , Articulação do Punho/patologiaRESUMO
We report a rare case of dystrophic calcinosis in a patient with rheumatoid arthritis in bilateral buttock lesions and the right elbow joint. The calcinosis was surgically removed because it caused severe local pain, possible infection, and difficulty in sitting. Because no recommended standard pharmacotherapy exists for dystrophic calcinosis, surgical treatment should be taken into consideration when calcinosis causes severe local pain or restricts activities of daily life.
Assuntos
Artrite Reumatoide/complicações , Calcinose/etiologia , Doenças do Tecido Conjuntivo/etiologia , Idoso , Artrite Reumatoide/patologia , Nádegas/diagnóstico por imagem , Nádegas/patologia , Nádegas/cirurgia , Calcinose/patologia , Calcinose/cirurgia , Doenças do Tecido Conjuntivo/patologia , Doenças do Tecido Conjuntivo/cirurgia , Articulação do Cotovelo/diagnóstico por imagem , Articulação do Cotovelo/patologia , Articulação do Cotovelo/cirurgia , Feminino , Humanos , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
PURPOSE OF REVIEW: Surgeons have long been striving to develop new surgical procedures to improve functional outcomes for a variety of hand and wrist deformities resulting from rheumatoid arthritis (RA). The purpose of this review is to assess the latest surgical outcomes related to hand and wrist surgery in the patient with RA. RECENT FINDINGS: There is a lack of outcome studies in RA hand and wrist surgery to justify many of the surgical procedures proposed for the treatment of the rheumatoid hand. However, advances made by the silicone metacarpophalangeal arthroplasty (SMPA) group regarding hand reconstruction for RA patients have improved patient care for this widely used procedure. Prophylactic versus therapeutic procedures are also discussed. SUMMARY: Rheumatoid hand is one of the earliest presentations of RA, and the progression of rheumatoid hand disease can be unpredictable. There are a number of surgical treatments for the rheumatoid hand and careful sequential planning of the surgical procedures can maintain patients' hand function and in many cases should enhance outcomes of the rheumatoid hand by correcting existing deformities. An early introduction to a hand surgeon can inform patients of available options and allow longitudinal assessment of structural and functional changes that could be treatable by future surgical interventions.
Assuntos
Artrite Reumatoide/cirurgia , Mãos/cirurgia , Procedimentos Ortopédicos/estatística & dados numéricos , Procedimentos Ortopédicos/tendências , Avaliação de Resultados em Cuidados de Saúde/métodos , Artrite Reumatoide/diagnóstico por imagem , Artrite Reumatoide/patologia , Artroplastia de Substituição de Dedo/instrumentação , Artroplastia de Substituição de Dedo/métodos , Diagnóstico Precoce , Mãos/diagnóstico por imagem , Mãos/patologia , Humanos , Articulação Metacarpofalângica/diagnóstico por imagem , Articulação Metacarpofalângica/patologia , Articulação Metacarpofalângica/cirurgia , Procedimentos Ortopédicos/métodos , Próteses e Implantes/estatística & dados numéricos , Próteses e Implantes/tendências , Implantação de Prótese/métodos , Implantação de Prótese/estatística & dados numéricos , Implantação de Prótese/tendências , Radiografia , Resultado do TratamentoRESUMO
A 62-year-old male with a 10-year history of seropositive rheumatoid arthritis (RA) developed gynecomastia 8 months after beginning oral low-dose methotrexate (MTX) therapy. Two months after folate supplementation, the gynecomastia symptoms improved. Gynecomastia associated with low-dose MTX is a rare occurrence, with only nine cases previously reported in the literature. This is the first report showing folate supplementation to be effective against gynecomastia following low-dose MTX. Although it occurs infrequently, gynecomastia associated with low-dose MTX therapy should be considered in male patients with RA.
Assuntos
Antirreumáticos/efeitos adversos , Artrite Reumatoide/patologia , Ácido Fólico/administração & dosagem , Ginecomastia/patologia , Metotrexato/efeitos adversos , Complexo Vitamínico B/administração & dosagem , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Suplementos Nutricionais , Relação Dose-Resposta a Droga , Ginecomastia/induzido quimicamente , Ginecomastia/dietoterapia , Humanos , Masculino , Mamografia , Pessoa de Meia-Idade , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
BACKGROUND: Rheumatoid arthritis is a chronic disease that can cause irreversible joint damage and significant disability. With a prevalence of 1%, it has a considerable cost to the community. Diagnosis is based on a combination of clinical and laboratory features. Patients typically present with a symmetrical polyarthritis of the small joints of the hands and feet accompanied by early morning stiffness and, occasionally, constitutional symptoms. OBJECTIVE: This review discusses the role of the general practitioner in the diagnosis and early management of rheumatoid arthritis. DISCUSSION: It is increasingly recognised that there is a 'window of opportunity' within which disease modifying antirheumatic drug therapy should be commenced to arrest progressive disease and joint destruction. Methotrexate is usually the first line agent in the management of rheumatoid arthritis but simple analgesia and nonsteroidal anti-inflammatory drugs are also important for symptom control.
Assuntos
Artrite Reumatoide/diagnóstico , Corticosteroides/uso terapêutico , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/epidemiologia , Artrite Reumatoide/patologia , Austrália/epidemiologia , Biomarcadores , Diagnóstico Diferencial , Ácidos Graxos Ômega-3/uso terapêutico , Humanos , Guias de Prática Clínica como AssuntoRESUMO
Etanercept-induced organizing pneumonia (OP) has not been reported in Japan. We describe the case of a rheumatoid arthritis patient who developed OP during etanercept treatment and discuss the possible mechanisms underlying the development of etanercept-induced OP and the existence of factors that predispose Japanese patients to drug-induced OP.